Novavax (NVDA) Could Be 42% Undervalued Following Losses And Shelf Registration
What the latest Novavax earnings mean for shareholders
Novavax (NVAX) just delivered a sharp turn in its financial story. Second quarter 2026 results showed revenue of US$56.7 million and a shift from net income to a net loss, alongside a fresh shelf registration filing.
See our latest analysis for Novavax.
The latest earnings release and shelf registration have come alongside mixed recent trading for Novavax. The share price has risen 2.71% over the last day and 8.61% over the past week, while the 30 day share price return is down 14.79%. Despite a year to date share price gain of 11.50%, the 1 year total shareholder return is down 5.02% and the 5 year total shareholder return has fallen 96.91%. This points to weakening long term momentum even as short term interest has increased.
If the recent volatility around Novavax has you thinking about other opportunities in healthcare, this could be a useful moment to scan 43 healthcare AI stocks.
Given Novavax’s sharp swing back into losses and the fresh shelf registration, some investors may see the recent share price bounce as an entry point. Others might prefer to wait. How does the current valuation compare?
Most Popular Narrative: 42.3% Undervalued
On the most followed narrative, Novavax’s fair value of $13.78 sits well above the last close at $7.95. That gap rests on specific assumptions about future licensing and royalties.
The license agreement with Pfizer, including a US$30m upfront payment and high mid single digit royalties on products containing Matrix M, adds a defined cash inflow and a potential recurring royalty stream that can support enterprise value beyond the core COVID vaccine business.
Want to see what really underpins that $13.78 figure? The narrative leans heavily on future margins, royalty streams, and a re-rated earnings multiple. Curious which assumptions do the heavy lifting here?
Result: Fair Value of $13.78 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Novavax story still hinges on partner execution and COVID vaccine demand, so any setback on either front could quickly challenge this undervalued narrative.
Find out about the key risks to this Novavax narrative.
Next Steps
The mix of risks and rewards around Novavax can feel finely balanced right now, so it helps to look past the headline moves and focus on the details. If you want to move quickly and shape your own view based on the full set of warning signs and potential upsides, start with 2 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Novavax?
If Novavax has sharpened your focus, do not stop there. Fresh ideas can often come from stocks you have not considered yet, so keep your opportunity set wide.
- Target potential value opportunities and see which companies stand out on quality and pricing with the 52 high quality undervalued stocks.
- Prioritise resilience by scanning companies that score well on financial strength through the solid balance sheet and fundamentals stocks screener (48 results).
- Spot lesser known opportunities before they become crowded by reviewing the screener containing 21 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com